Hims & Hers Health shares gain more than 3% after strong revenue growth and subscriber gains outweigh renewed operating losses

Hims & Hers Health shares gain more than 3% after strong revenue growth and subscriber gains outweigh renewed operating losses
Hims & hers surges 3.02% today

Hims & Hers Health Inc (HIMS) advanced 3.02% after delivering strong revenue growth and subscriber gains in its latest quarter, even as the company swung back to operating losses. The rebound looks limited, with the stock still trading below all key moving averages and bearish momentum signals persisting.

HIMS price prediction
24H -1.02%
$17.39
48H -0.28%
$17.52
7D 0.57%
$17.67
1M -38.19%
$10.86
3M -53.5%
$8.17
6M -72.4%
$4.85
12M -59.25%
$7.16
Current price: $17.57 0.0250 0.14%
Real-time Data 10:52
Daily range 17.15 Arrow from to Icon 18.54
Weekly range 17.15 Arrow from to Icon 20.44
Loading...

Highlights

  • Hims & Hers Health posted a $66.1 million operating loss and a $33 million net loss for the third quarter of 2026, reversing its prior-year profit.
  • Revenue increased 49% year-over-year to $890.4 million and subscribers reached 2.8 million, with the company expanding its product lineup and obtaining access to Zepbound.
  • Shares of Hims & Hers Health trade below key technical levels with strong bearish signals, an expected range of $16.43 to $19.72, and a very high probability of a downward move in the next five days.

Subscriber growth and new products amid widening operating loss

Hims & Hers Health reported a return to operating losses in the third quarter of 2026, posting a $66.1 million operating loss and a net loss of $33 million, reversing its prior-year profit. Revenue climbed 49% year-over-year to $890.4 million, and subscriber numbers rose 13% to 2.8 million despite a quarterly decline due to reduced marketing and a brand transition. The company expanded its product lineup by launching the Peptides+ platform and secured access to Eli Lilly's Zepbound, while a company officer filed to sell 3,518 Class A shares under a Rule 10b5-1 plan.

Anton Kharitonov, expert at Traders Union, sees little appeal in Hims & Hers Health given its return to operating losses despite headline revenue growth. He notes that the stock remains trapped below major moving averages and key resistance, even after a modest rebound. Momentum and sentiment remain firmly bearish, with persistent selling pressure overshadowing improving top-line numbers. Kharitonov highlights that the recent news of a product launch and subscriber gains does not offset the deteriorating fundamentals. "With the technical and financial picture both signaling caution, I do not see a convincing case for upside here."
Viktoras Karapetjanc, expert at Traders Union, focuses on the underlying business fundamentals and future opportunities. He views the strong 49% revenue jump and expanded product portfolio as maintaining a bullish structure despite the temporary operating loss. Improved access to high-demand therapies and a sustained subscriber base point to healthy long-term prospects. Karapetjanc remains confident that growth initiatives will outweigh short-term fluctuations. "The market's volatility offers several setups for buyers, and further growth for Hims & Hers Health looks likely."
Sholanke Dele, market strategist, adopts a cautious stance on Hims & Hers Health as macro and sentiment risks dominate. He points out the reversal to net losses and a quarterly dip in subscribers as signals of waning investor conviction. The ongoing share sale by a company officer further weighs on sentiment, hinting at internal uncertainty. "Given the technical weakness and negative news flow, I expect downside pressure to persist in the short term."
Hims & Hers Health Inc. asset chart
Hims & Hers Health Inc. price dynamics. Source: TradingView.

Persistent bearish momentum as price holds below key averages

Hims & Hers Health is trading below all major moving averages, with the price at $18.08 under the MA-20 at $24.72, MA-50 at $27.22, and MA-200 at $26.59. This configuration highlights sustained selling pressure and a clearly bearish setup across short, medium, and long-term trends. The nearest resistance is at $18.54, and support stands at $17.15, with the Ichimoku Kijun level at $23.71 reinforcing the downward technical bias. Momentum indicators remain strongly bearish: the MACD is negative, ADX points to ongoing selling, and the RSI, Stochastic RSI, and CCI all indicate an oversold condition. The Bull/Bear Power (BBP) is deeply negative at -3.27, and the Awesome Oscillator remains below zero, reflecting seller dominance. Trading is occurring near session highs after a 5.58% intraday gap and 3.02% advance, but short-term technical signals still point to lingering downward momentum amid elevated intraday volatility of 8.10%.

Earlier, analysts noted that Hims & Hers Health continued to exhibit persistent downside momentum and technical fragility despite recent strategic initiatives. The current analysis reinforces this assessment, with bearish pressures still in control and the prevailing risk centered on whether the stock can hold support at $17.15 over the coming sessions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.